Structure Therapeutics

For those that face Type 2 #diabetes, there can often be a heavy amount of misconceptions and stereotypes. We are supporting our partners at Beyond Type 2 this week as they fight to end the stigma around Type 2, creating a more honest and understanding narrative. Learn more below.

We had a wonderful time hosting our families for the day at our office and lab space in Shanghai. During our family day, we toured our facilities and showed our loved ones what a day in the #biotech world looks like. We believe in the importance of #STEM education, and our children were especially inspired by the roles scientists play in making a difference for patients living with disease. Following the office tour, we enjoyed a nice dinner with great food and even greater company.

Chronic diseases, including obesity, are rapidly increasing worldwide, escalating the demand for life-changing medicines. At Structure, we are determined to address these devastating #obesity figures with innovative, #smallmolecule medicines without the inherent limitations of peptides and biologics. Oral small molecule drugs can  offer improved patient experience and broad access. Learn more about our platform here: https://lnkd.in/eHpMkXRm

Our internal global recognition program, Structure Impact, recognizes our team members' exceptional work and celebrates those who embody our core values day in and day out. We're excited to introduce you to our Structure Salute recipients each quarter and share their above and beyond employee contributions.

Our full team came together for an inspiring company retreat giving us the opportunity to align our mission for the future. During three action-packed days with numerous breakout sessions and activities, we fostered stronger connections, reaffirmed our dedication to our core values and shared insights from our individual teams to help further advance our patient-focused vision of making medicines more accessible to all. See below for a highlight reel of some of the trip's best moments.

That's a wrap for #ADA2024! Our team enjoyed showcasing data from our Phase 1b/2a study of GSBR-1290, a #smallmolecule #GLP1 receptor agonist in development for people living with #obesity and #type2diabetes. Following our time at the event, we're feeling inspired by the work being done in our industry for patients and look forward to sharing more about our innovative science. 

In commemoration of the three-day Chinese #DragonBoatFestival celebration, the team at our Shanghai office hosted a series of activities true to Chinese tradition and culture. From knitting and making sachets to creating leaf fans, we enjoyed crafting while snacking on an assortment of dumplings and rice cakes. 

Our CEO Raymond Stevens recently spoke with CNBC Fast Money's Melissa Lee to discuss our progress with our #GLP1 receptor agonist drug, GSBR-1290, and its potential to become a best-in-class oral treatment for people living with #obesity, and the scalability of #smallmolecule drugs. Watch the full clip here:  https://lnkd.in/eiuBxUz7 

We're excited to launch a new employee spotlight series introducing you to some of the key players on our team! First up, meet our Director, Medical Writing Chelsea Olsen, PhD. As a valued leader and mentor, we're happy to have Chelsea within our clinical team to help run our clinical trials efficiently as we design #smallmolecule medicines to transform patients’ lives across the globe.

We're pleased to share positive topline data from our 12-week Phase 2a #obesity study of our oral, non-peptide GLP-1 receptor agonist, GSBR-1290, along with positive data from our capsule to tablet PK study. GSBR-1290 demonstrated clinically meaningful and statistically significant weight loss and generally favorable safety and tolerability result. We look forward to starting our Phase 2b study, which is on track to begin in the fourth quarter of this year. Read the full announcement here: https://lnkd.in/eJp_qPuS